Trusted Resources: Education
Scientific literature and patient education texts
A Guide to Understanding MPS I (Hurler, Hurler-Scheie, and Scheie Syndromes)
source: National MPS Society
year: 2021
summary/abstract:What Is MPS I?
Mucopolysaccharidosis I (MPS I) is a rare genetic disorder that affects the entire body. It is also known as Hurler syndrome, named after Dr. Gertrude Hurler, a general practitioner, who in 1919 first described a boy and girl with severe symptoms of the condition. In 1962, Dr. Harold Scheie, an ophthalmologist, described individuals who displayed attenuated (less severe) symptoms and primarily were affected by corneal clouding. This apparently new condition was named Scheie syndrome (also temporarily known as MPS V) and was thought to be a different disease from Hurler syndrome. In the 1970s, there were several reports of individuals whose symptoms of intermediate severity did not fit clearly in either syndrome, and consequently, were categorized as Hurler-Scheie syndrome.
If you are a parent of a newly diagnosed child, or someone who has been diagnosed with MPS I yourself, it is important to remember that there is a wide spectrum of severity in how MPS I shows up and progresses:
It can be an attenuated (less severe) form that usually manifests in adolescence and progresses slowly, which is called Scheie syndrome and is less common.
It can be an intermediate form that usually manifests in late childhood, has some features of both the attenuated and severe forms, and progresses at an intermediate pace, which is called Hurler-Scheie syndrome.
read more
Related Content
-
Disease Manifestations in Mucopolysaccharidoses and Their Impact on Anaesthesia-Related Complications-A Retrospectiv...Patients with mucopolysaccharidoses (MPS...
-
Nationwide Newborn Screening Program for Mucopolysaccharidoses in Taiwan and An Update of the “Gold Standard&#...Mucopolysaccharidoses (MPSs) are a group...
-
Understanding How Enzymes Work and Affect Our Bodyhttps://slideplayer.com/slide/7566393/...
-
Lysosomal Storage Disorders: Clinical, Biochemical and Molecular Profile From Rare Disease Centre, IndiaLysosomal storage disorders (LSDs) are a...
-
EMA Grants Orphan Drug Designation to JR-171 for the Treatment of Mucopolysaccaridosis Type I (MPS I)JCR Pharmaceuticals Co., Ltd. announced ...
-
Evidence of Treatment Benefits in Patients With Mucopolysaccharidosis Type I-Hurler in Long-Term Follow-Up Using a N...We developed a brain and spine magnetic ...
-
MPS IIIA (Sanfilippo Syndrome, Type A) in a 7-Year-Old Girlhttps://slideplayer.com/slide/13595382/...